RYAH Group (CSE: RYAH) has named a new vice president of intellectual property commercialization. The company has appointed Radka Milanova, PhD, to the new position; as a member of the senior management team, Milanova will work to ensure a consistent and strong focus on the company’s IP strategy, with an objective to expand and monetize it. Milanova will also serve on RYAH’s advisory board as a scientific advisor where her extensive international network will be invaluable as she works to promote RYAH business development and investment opportunities. With more than two decades of experience in the pharmaceutical and nutraceutical arena, Milanova has a proven track record of leading R&D programs and facilitating new product developments; she also has impressive expertise in negotiating and conducting complex multicompany collaborations. She has championed four Investigational New Drug (“IND”) applications and two successful New Drug Applications (“NDA”) as well as authored eight granted patents and seventeen peer-reviewed publications and led funding for $2 million in research grants. RYAH also noted that management and company auditors are working diligently to complete the documents related to the cease-trade order. The company anticipates filling all necessary documents in the near future. “Radka brings enormous talent, leadership experience and focus to our IP commercialization efforts,” said RYAH CEO Dr. Dave Richards in the press release. “She is already contributing ideas for new products and product enhancements, introducing and engaging new potential partners, and bringing welcome diversity of perspectives to the team based on her unique background and skillset. I’m delighted she’s on our team.”
To view the full press release, visit https://ibn.fm/MjpEC
About RYAH Group Inc.
RYAH is a big data and technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other nutraceuticals administered through its innovative IoT-connected devices including the world’s only smart inhalers. RYAH’s robust big data platform, the only one of its kind in this space, aggregates and analyzes HIPAA-compliant user data, helping users, patients and doctors personalize treatments, control dosages, and better predict and monitor outcomes. The data and derived insights are also highly valuable for hospitals, clinicians, medical scientists, insurance providers, dispensaries, licensed growers, producers and pharmaceutical companies, and to monitor and manage formulation effects on patients based on dosages, strains, demographics, specific conditions and a range of other factors. Exciting new directions include R&D in the realm of blockchain, NFTs and cryptocurrency that will pave the way toward successful commercialization of RYAH’s big data assets. Through the above, a relentless focus on innovation and track record of developing win-win collaborative partnerships within relevant industries, RYAH is continuously building a unique and highly valuable IP portfolio enabling significant commercial traction globally. For more information about the company, please visit www.RyahGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
